US-based Eli Lilly and Company has issued a statement today regarding the novel coronavirus' impact on insulin and other products
Eli Lilly and Company has issued a statement today regarding the novel coronavirus.
"Among the concerns raised due to the impact of the novel coronavirus is whether patients can count on a reliable supply of medicine," the statement read. "Lilly does not anticipate shortages for any of our products, including all forms of insulin."
The company added that since the initial outbreak, it has been closely monitoring its supply chain for potential impact to the supply of our medicines around the world. "Lilly does not source active pharmaceutical ingredients (API) for any of its approved medicines from China, and our insulin manufacturing sites in the US and Europe have not been impacted by coronavirus," the statement explained.
Lilly insulin and other medicines are available, as normal, in US pharmacies.
"Globally, our manufacturing network is fully operational and taking steps to prevent impact. We're also in close communication with key suppliers to ensure appropriate supplies of raw materials. As the global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicines." the statement concluded.